Legal Showdown: Supreme Court to Review E-commerce ‘Safe Harbour’ in Landmark Drug Regulation Case
The Supreme Court of India has waded into a critical legal battlefield that pits the burgeoning e-commerce sector against public health mandates. In a significant development, a special bench of the apex court, comprising Justices Ahsanuddin Amanullah and R. Mahadevan, has issued notice to e-commerce giant Snapdeal and its directors, Kunal Bahl and Rohit Kumar Bansal. The court is acting on a Special Leave Petition (SLP) filed by the Karnataka government, which seeks to challenge a 2022 Karnataka High Court ruling that quashed criminal proceedings against the platform.
At the heart of the litigation is the extent to which digital intermediaries can shield themselves under the "safe harbour" provisions of the Information Technology (IT) Act, 2000, when third-party sellers on their platforms facilitate the sale of regulated, prescription-only drugs.
The Genesis: A Case of Unregulated Pharmaceutical Sales
The legal saga dates back to 2019, when a drugs inspector in Belagavi, Karnataka, initiated criminal proceedings under the Drugs and Cosmetics Act, 1940. The complaint centered on the sale of "Suhagra-100," a Schedule H prescription medication used for the treatment of erectile dysfunction.
According to the prosecution, the transaction occurred on the Snapdeal marketplace through a third-party seller identified as M/s Herbal Healthcare. The investigation alleged two primary violations:
- Lack of Licensure: The seller reportedly operated without a valid drug license, which is a mandatory requirement for the sale of pharmaceutical products in India.
- Evasion of Medical Oversight: The platform allegedly facilitated the sale without requiring the buyer to produce a valid doctor’s prescription, a direct violation of the Drugs and Cosmetics Rules, 1945.
Following the initial complaint, a judicial magistrate in Belagavi took cognizance of the matter and issued summons to Snapdeal, its top leadership, and the vendor. This set the stage for a protracted legal dispute regarding corporate accountability in the digital age.
Chronology of the Dispute
- 2019: A drugs inspector files a criminal complaint in Belagavi, alleging violations of the Drugs and Cosmetics Act, 1940, concerning the unauthorized online sale of Suhagra-100.
- 2019-2021: Snapdeal and its directors move to the Karnataka High Court to quash the criminal proceedings, citing their status as a mere intermediary.
- February 2022: The Karnataka High Court rules in favor of Snapdeal, quashing the criminal case. The court cites a lack of "application of mind" by the magistrate and affirms the platform’s right to "safe harbour" under Section 79 of the IT Act.
- July 15, 2024: The Supreme Court issues notice to Snapdeal on the Karnataka government’s SLP, reopening the debate on intermediary liability.
- August 10, 2024: The Supreme Court is scheduled to hear the matter, clubbed with similar petitions, marking a pivotal moment for e-commerce compliance.
The High Court’s Rationale: The ‘Safe Harbour’ Shield
The Karnataka High Court’s 2022 decision to quash the criminal case was anchored in the interpretation of Section 79 of the IT Act, 2000. This section provides legal immunity to intermediaries—defined as platforms that host third-party content—provided they maintain a "neutral" role and strictly adhere to due diligence requirements as prescribed by the government.
The High Court observed that the magistrate’s order to summon the directors lacked sufficient evidence of their direct involvement in the specific transaction. Furthermore, the court emphasized that as an intermediary, Snapdeal could not be held vicariously liable for the illegal acts of its third-party vendors, provided the platform followed the statutory "notice and takedown" protocols.
For the e-commerce industry, the 2022 ruling was a major victory. It reinforced the belief that marketplaces function merely as conduits and that the burden of regulatory compliance regarding product-specific laws (such as drug or food safety laws) rests primarily with the vendor.
The State’s Argument: Public Health Over Digital Immunity
The Karnataka government, represented by Additional Advocate General Aman Panwar, has taken a firm stance that the IT Act cannot be used as a "blanket immunity" to override public health legislation.
The state’s argument rests on three core pillars:
- The Primacy of Sectoral Laws: The government contends that the Drugs and Cosmetics Act is a special law enacted to protect public health. It argues that safe harbour provisions in the IT Act—a general law—should not be interpreted in a way that defeats the purpose of stringent drug regulations.
- Failure of Due Diligence: The prosecution argues that Snapdeal failed to fulfill its due diligence obligations under Section 79(2)(c). By allowing a prescription drug to be sold without verifying the seller’s license or the buyer’s prescription, the platform arguably failed to act as a "neutral" host, thereby forfeiting its safe harbour protection.
- Duty of Care: The state posits that online marketplaces have a higher duty of care when hosting categories of products that, if mishandled, can pose significant health risks to the populace.
Implications for the Indian E-commerce Ecosystem
This Supreme Court hearing is not merely about a single drug transaction; it is a bellwether for the future of Indian e-commerce.
The Impact on Marketplace Models
If the Supreme Court rules in favor of the Karnataka government, it could necessitate a massive overhaul of how e-commerce platforms operate. Marketplaces might be forced to adopt more aggressive verification protocols for sellers in "sensitive" categories, such as pharmaceuticals, nutraceuticals, and medical devices. This would increase operational costs and potentially slow down the onboarding of smaller third-party sellers.
Redefining ‘Due Diligence’
The current definition of "due diligence" for intermediaries is often viewed as a compliance exercise—ensuring that terms of service are updated and grievance officers are appointed. A ruling in this case could redefine due diligence to include "active monitoring" or "product-specific vetting," effectively narrowing the safe harbour protection that has underpinned the growth of platforms like Amazon, Flipkart, and Snapdeal.
The Conflict of Laws
The case brings to the fore the classic conflict between general digital legislation and specific sectoral regulations. As more industries go digital, the judiciary must determine whether the IT Act’s immunity is absolute or conditional. Legal experts suggest that the Supreme Court may provide clarity on whether "intermediary" status is a total shield or if it evaporates the moment a platform hosts a product that violates a public welfare statute.
A Wider Context: The E-Pharmacy Debate
It is important to note that this case runs parallel to the broader, unresolved national debate regarding the regulation of e-pharmacies in India. While the government has periodically drafted rules to regulate the online sale of medicines, a comprehensive, pan-India framework remains elusive.
The absence of clear, codified rules for e-pharmacies has left a regulatory vacuum. In this void, platforms have often leaned on the IT Act to justify their operations. By intervening in the Snapdeal matter, the Supreme Court is indirectly addressing the systemic lack of oversight in the online pharmaceutical trade.
Conclusion: The Road Ahead
As the hearing date of August 10 approaches, the stakes could not be higher. For the e-commerce sector, a favorable outcome is essential to maintain the "intermediary" business model that has defined the digital revolution in India. For the government and regulators, the case represents a crucial opportunity to ensure that the ease of digital commerce does not come at the expense of consumer safety.
The Supreme Court’s eventual verdict will likely set a judicial precedent that influences how platforms handle prohibited or restricted goods. Until then, the case stands as a stark reminder that in the digital economy, the convenience of a "click-to-buy" culture must be balanced against the robust safeguards of the rule of law. Whether the "safe harbour" of the IT Act is robust enough to weather the demands of public health policy will be the defining question of this high-profile litigation.
